Citadel Advisors
TENX icon

Citadel Advisors’s Tenax Therapeutics TENX Stock Holding History

Citadel Advisors’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.44M Buy
152,516
+22,988
+18% +$311K ﹤0.01% 5674
2025
Q4 		$1.58M Buy
129,528
+86,275
+199% +$750K ﹤0.01% 6399
2025
Q3 		$329K Buy
43,253
+32,908
+318% +$201K ﹤0.01% 10143
2025
Q2 		$60.4K Sell
10,345
-12,796
-55% -$74K ﹤0.01% 11672
2025
Q1 		$152K Buy
+23,141
New +$148K ﹤0.01% 10858
2024
Q1 		– Sell
-632
Closed -$13.9K – 15424
2023
Q4 		$13.9K Buy
632
+444
+236% +$10.7K ﹤0.01% 12905
2023
Q3 		$4.43K Buy
+188
New +$4.76K ﹤0.01% 13486
2022
Q3 		– Sell
-46
Closed -$22K – 13596
2022
Q2 		$22K Buy
+46
New +$46.1K ﹤0.01% 12370
2021
Q3 		– Sell
-13
Closed -$44K – 14639
2021
Q2 		$44K Buy
13
+3
+30% +$9.51K ﹤0.01% 13380
2021
Q1 		$30K Sell
10
-7
-41% -$25K ﹤0.01% 13031
2020
Q4 		$51K Buy
+17
New +$31.3K ﹤0.01% 10563
2020
Q3 		– Sell
-13
Closed -$18K – 10722
2020
Q2 		$18K Buy
+13
New +$19.1K ﹤0.01% 9570
2019
Q4 		– Sell
-15
Closed -$29K – 9753
2019
Q3 		$29K Buy
15
+9
+150% +$18.7K ﹤0.01% 8858
2019
Q2 		$14K Buy
+6
New +$14.5K ﹤0.01% 8993
2019
Q1 		– Sell
-7
Closed -$14K – 9856
2018
Q4 		$14K Buy
+7
New +$38.5K ﹤0.01% 8859
2018
Q1 		– Sell
-3
Closed -$43K – 8774
2017
Q4 		$43K Hold
3
– – ﹤0.01% 7671
2017
Q3 		$30K Buy
3
+2
+200% +$29.7K ﹤0.01% 7288
2017
Q2 		$30K Hold
1
– – ﹤0.01% 7205
2017
Q1 		$19K Buy
+1
New +$36.3K ﹤0.01% 7259
2016
Q2 		– Hold
0
– -$30K – 7396
2016
Q1 		– Hold
0
– – – 6379

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's TENX Position: Q1 2026 in Review

Citadel Advisors increased its Tenax Therapeutics (TENX) stake by 18% in Q1 2026, buying an estimated $311K and bringing the position to 152,516 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #5674.

Citadel Advisors first reported a position in TENX in Q1 2017 and has held it in 19 quarters since. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Citadel Advisors held 152,516 shares of Tenax Therapeutics worth $2.44M as of Q1 2026.
  • Citadel Advisors bought 22,988 Tenax Therapeutics shares in Q1 2026, an estimated $311K.
  • Tenax Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5674 holding.
  • Citadel Advisors first reported a position in Tenax Therapeutics in Q1 2017 and has held it in 19 quarters since.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.